PharmSee anchors most Pharmacy First (PF) revenue analysis on a simple per-site ceiling: £6,000 per pharmacy per year. That number comes from a clean arithmetic calculation — £15 per completed PF clinical pathway, multiplied by 400 consultations per year per pharmacy. It is a first-principles planning anchor, not a measured number, and it is crucial to understand exactly what it does and does not claim before reading any PharmSee regional PF analysis.
This article unpacks the £6,000 anchor, explains the assumptions baked into it, and flags where NHSBSA's real consultation-volume data (when published Q4 2026) will either validate or adjust the figure.
The £6,000 calculation, step by step
The Pharmacy First service pays pharmacies a fixed consultation fee for each of seven clinical pathways: sinusitis, sore throat, acute otitis media, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections in women. The fee is £15 per completed clinical pathway consultation. The NHS monthly-per-site contribution (the "availability fee") is a separate payment stream and is not part of the £6,000 ceiling.
PharmSee's assumption is 400 completed consultations per pharmacy per year. That works out to:
- ~7.7 consultations per week across a 52-week trading year
- Or roughly one-and-a-half per working day for a 5-day-a-week operating pharmacy
- £15 × 400 = £6,000
The 400 number is not a measured throughput. It is a PharmSee analytical judgement, grounded in the 2023–2025 ramp of PF uptake and in observations of consultation-room capacity at a typical high-street urban pharmacy. Rural and seasonal pharmacies should be expected to run lower; busy urban sites can run higher.
What the £6,000 ceiling does NOT claim
Three clarifications that have caused confusion in past cycles:
1. It is not a measured revenue figure. PharmSee does not have per-pharmacy consultation counts — NHSBSA publishes aggregate PF revenue but does not break down by postcode. The £6,000 is a planning anchor; PharmSee's regional PF analyses label it as an estimate every time it is quoted.
2. It is not uniform across pharmacies. A city-centre community pharmacy with a walk-in footfall of 500+ per day and a dedicated consultation room probably exceeds 400 PF consultations per year. A rural branch operating four days a week with no dedicated consultation room probably runs substantially below. The £6,000 is the mid-range planning ceiling, not the median.
3. It is not inclusive of the monthly fee or the walk-in promotion fee. The NHS also pays pharmacies a small monthly availability fee for being on the PF register and a referral-promotion supplement in specific circumstances. Those add to per-site PF revenue but PharmSee quotes them separately so that the £6,000 stays clearly interpretable.
What PharmSee DOES claim with confidence
Two anchor numbers are clean:
- The £15 per consultation fee — this is set by NHS England and the current PF service specification. It is not a PharmSee estimate.
- 400 consultations × £15 = £6,000 exactly — given the assumption, the arithmetic is trivial and invariant.
The only thing PharmSee is estimating is the 400-consultation throughput assumption. The £6,000 headline follows mechanically from that.
PharmSee's urban / rural split on capture rate
Internal cycles use two capture-rate regimes to capture the urban / rural difference:
- Urban capture rate: 55–65% of the 400-consultation ceiling, equivalent to 220–260 PF consultations per year and £3,300–£3,900 per site
- Rural / seasonal capture rate: 35–45% of the ceiling, equivalent to 140–180 PF consultations per year and £2,100–£2,700 per site
These percentages are PharmSee analytical judgements based on workforce observations and referral-relationship patterns. They are not measured capture rates. Any article that cites them should say so, and PharmSee's cycle 13–15 discipline is to flag them as estimates every time.
What NHSBSA's 2026 consultation data will test
NHSBSA is expected to release per-pharmacy Pharmacy First consultation volumes for the 2025/26 financial year in Q4 2026. When that data arrives, three things will be testable:
- Is 400 per year the correct planning anchor? The NHSBSA national average will resolve whether PharmSee's 400-consultation assumption is a mid-range figure or whether the real distribution sits higher or lower.
- Is the urban / rural split the right framing? If NHSBSA per-postcode data shows a flatter distribution than PharmSee's 55–65% vs 35–45% regime suggests, the split will need to widen or contract.
- Are there regional concentrations that the estimate is missing? PharmSee's cycle 14 "Liverpool Pharmacy First opportunity" piece projected ~£522k per year across 87 operating L1 pharmacies at the £6,000 ceiling. NHSBSA data will either validate that figure or tighten it.
The commercial implication for operators
The £6,000 anchor matters because it is how operators size Pharmacy First as a revenue-growth lever. At a 100-branch mid-size chain — Cohens, Day Lewis, Rowlands, Weldricks — the ceiling is 100 × £6,000 = £600,000 per year in PF revenue before the urban / rural capture rate adjustment. After an 50% average capture, the realistic figure is ~£300,000. That is real money relative to small-chain dispensing revenue, but it is not transformative, and operators should size PF expectations accordingly rather than treating the £6,000 ceiling as the planning figure for every branch.
The policy implication
If NHSBSA Q4 2026 data shows PF average consultations per site are running substantially below 400, the political conversation shifts from "PF is working" to "PF needs rescoping". Conversely, if the average comes in meaningfully above 400 — which is possible for urban England, where dedicated consultation rooms and walk-in footfall both support higher throughput — then the £6,000 anchor understates the programme's real commercial contribution to community pharmacy viability.
Use PharmSee to model your own chain
Our Pharmacy First revenue calculator lets you plug in branch counts and your own capture-rate assumptions. The regional revenue leak analysis models what an unbalanced capture rate looks like across the English regions.
Takeaway
PharmSee's £6,000-per-site Pharmacy First ceiling is a clean £15 × 400 arithmetic anchor. It is not a measured revenue figure, and it depends on a 400-consultation-per-year throughput assumption that NHSBSA's Q4 2026 per-site consultation data will test. The £15 unit fee is clean. The 400 assumption is an analytical judgement. Quoting both parts clearly is what makes PharmSee's PF analysis defensible.
PharmSee Pharmacy First methodology anchor, cycle 16 — reality-check draft 11 April 2026.